Do CBD Drops Help with Anxiety?


Kelly Weimert

September 5th, 2017

Policy


Businessman covering eyes

40 million adults in the United States are affected by anxiety-related disorders and countless drugs have been developed to help treat and manage those disorders. From benzodiazepines (like Valium and Xanax) to selective serotonin reuptake inhibitors (like Prozac and Zoloft), the pharmaceutical industry provides a lot of options with respect to managing anxiety.

The problem is, nearly all of those drugs come with unwanted side effects that can range from weight gain to brain fog to full-on addiction, so more and more people are looking for safer alternatives to anxiety treatment. And, as it turns out, CBD oil just might be the safe alternative anxiety sufferers have been waiting for.

But first, what is CBD oil?

CBD stands for cannabidiol, which is a chemical compound found in marijuana that’s not responsible for getting you stoned. The psychoactive chemical in cannabis—the one that makes you feel high—is called tetrahydrocannabinol (THC). Therefore, consuming CBD alone won’t make you feel intoxicated or impair you from doing any of your normal day-to-day activities like working, driving, or anything else that requires concentration.

How might CBD oil affect anxiety?

The effects of CBD oil on anxiety are still being studied, but the research on it so far is very promising. Growing evidence from clinical, epidemiological, and experimental studies suggests that CBD’s anti-anxiety properties can help manage a variety of anxiety-related disorders, including:

  • Social anxiety disorders
  • Generalized Anxiety Disorder
  • Obsessive Compulsive Disorder
  • Mild to moderate depression
  • Post-Traumatic Stress Disorder
  • Panic disorders

Researchers are finding that CBD oil works similarly to traditional anxiety-management medications in several ways.

One way is that CBD is what’s called a 5-HT1A agonist. 5-HT1A is a serotonin receptor, which is what a lot of pharmaceutical medications target to manage anxiety symptoms, called serotonin reuptake inhibitors (SSRIs). There’s evidence that suggests this particular agonist in CBD is a mechanism that works very similarly to SSRIs when it comes to abating feelings of anxiety but with fewer potential side effects.

The other way CBD oil might improve anxiety is through a process called hippocampal neurogenesis. Your hippocampus is the area in your brain responsible for memory formation and cognition. Patients with depression and anxiety who receive brain scans often show a smaller hippocampus than people without, and those whose symptoms have improved over time frequently show an influx of new neurons in this area.

A study wherein mice were repeatedly administered CBD found that the chemical might assist the hippocampus in generating these new neurons, which is a process known as hippocampal neurogenesis.

How CBD has reduced anxiety in real people

Animal studies and scientific speculation aside, the impact of CBD oil on real people using it has also been highly promising. In a study of patients with Generalized Anxiety Disorder in Brazil, participants given CBD over a period of time reported a significant decrease in their anxiety symptoms, which was validated by brain scans showing consistency with anti-anxiety effects.

In another study, which focused on patients suffering from Social Anxiety Disorder, participants were tasked with performing a simulated public speaking test. Researchers found that in addition to patients reporting less anxiety, objective anxiety indicators like rapid heart rate and high blood pressure were also reduced after taking CBD oil without impacting participants’ cognitive function.

Where to buy CBD oil

Ready to try CBD oil for yourself? Turns out, there are plenty of online retailers just a click away. And because CBD doesn’t contain psychoactive properties, it’s totally legal to buy and consume, no matter the state you live in.

Check out the following online retailers:

Charlotte’s Web

The CBD Distillery

Healthy Hemp Oil

Bottom line

Due to cannabis’ Schedule I drug classification by the federal government, research on its chemicals and their specific impact has been limited. However, with its increased legality and accessibility, more clinical studies are available, and in those done so far, CBD oil has shown a lot of promise with respect to managing symptoms of anxiety safely and comfortably.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Kelly Weimert

Kelly is a full-time freelance writer based in Austin, TX. A happy hybrid of geek and hippie, when she's not nestled into her couch crankin' out crafty prose with her miscreant Chihuahua, you can find her frolicking outside to keep her sanity in check.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading